BRNS — Barinthus Biotherapeutics Share News
0.000.00%
Last trade - 00:00Brief: Vaccitech PLC Announces Positive Data for Study in People with Chronic Hepatitis B
Brief: Vaccitech Reports Full-Year 2022 Financial Results And An Update On Corporate Developments
Vtp-200 Was Generally Well-Tolerated With No Product-Related Serious Adverse Events
Brief: Vaccitech Appoints Industry Veteran, Nadège Pelletier As Chief Scientific Officer
Brief: Vaccitech Reports Third Quarter 2022 Financial Results
Brief: Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial
Brief: Vaccitech Doses First Patients In HBV003, A Phase 2B Clinical Trial Of VTP-300 Immunotherapeutic Candidate For Chronic HBV Patients
Brief: Vaccitech PLC Says Board Appointed Gemma Brown As CFO
Brief: Vaccitech Promotes Gemma Brown As Chief Financial Officer
Brief: Vaccitech PLC Files For Mixed Shelf Of Up To $200 Million
Brief: Vaccitech Q2 Earnings Per Share $0.41
NASDAQ RESUMED AT 12:16 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:06 PM
Brief: Vaccitech PLC Files For Offering Of 2.2 Million Ordinary Shares, Represented By Adss, By Selling Shareholders
Vaccitech rises on promising interim data from hepatitis B study
Brief: Vaccitech Announces Update On VTP-300 Trial
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 03:40 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:01 PM
Brief: Vaccitech Reports Q1 2022 Results